| DeepSynergy: predicting anti-cancer drug synergy with Deep Learning K Preuer, RPI Lewis, S Hochreiter, A Bender, KC Bulusu, G Klambauer Bioinformatics 34 (9), 1538-1546, 2018 | 546 | 2018 |
| Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ... Nature communications 10 (1), 2674, 2019 | 327 | 2019 |
| Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study VA Papadimitrakopoulou, YL Wu, JY Han, MJ Ahn, SS Ramalingam, ... Annals of Oncology 29, viii741, 2018 | 272 | 2018 |
| Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives KC Bulusu, R Guha, DJ Mason, RPI Lewis, E Muratov, YK Motamedi, ... Drug discovery today 21 (2), 225-238, 2016 | 214 | 2016 |
| Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo CD Mohan, H Bharathkumar, KC Bulusu, V Pandey, S Rangappa, ... Journal of Biological Chemistry 289 (49), 34296-34307, 2014 | 174 | 2014 |
| canSAR: updated cancer research and drug discovery knowledgebase KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani Nucleic acids research 42 (D1), D1040-D1047, 2014 | 106 | 2014 |
| canSAR: an integrated cancer public translational research and drug discovery resource MD Halling-Brown, KC Bulusu, M Patel, JE Tym, B Al-Lazikani Nucleic acids research 40 (D1), D947-D956, 2012 | 94 | 2012 |
| Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial J Chmielecki, T Mok, YL Wu, JY Han, MJ Ahn, SS Ramalingam, T John, ... Nature communications 14 (1), 1071, 2023 | 80 | 2023 |
| Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. C Zhou, F Imamura, Y Cheng, I Okamoto, BC Cho, MC Lin, M Majem, ... Journal of Clinical Oncology 37 (15_suppl), 9020-9020, 2019 | 68 | 2019 |
| Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer A Gogleva, D Polychronopoulos, M Pfeifer, V Poroshin, M Ughetto, ... Nature communications 13 (1), 1667, 2022 | 61 | 2022 |
| Novel adamantanyl-based thiadiazolyl pyrazoles targeting EGFR in triple-negative breast cancer A Sebastian, V Pandey, CD Mohan, YT Chia, S Rangappa, J Mathai, ... ACS omega 1 (6), 1412-1424, 2016 | 52 | 2016 |
| Microwave-assisted synthesis, characterization and cytotoxic studies of novel estrogen receptor α ligands towards human breast cancer cells H Bharathkumar, CD Mohan, H Ananda, JE Fuchs, F Li, S Rangappa, ... Bioorganic & medicinal chemistry letters 25 (8), 1804-1807, 2015 | 47 | 2015 |
| Orthologue chemical space and its influence on target prediction LH Mervin, KC Bulusu, L Kalash, AM Afzal, F Svensson, MA Firth, I Barrett, ... Bioinformatics 34 (1), 72-79, 2018 | 43 | 2018 |
| Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer … JE Gray, MJ Ahn, GR Oxnard, FA Shepherd, F Imamura, Y Cheng, ... Clinical cancer research 29 (17), 3340-3351, 2023 | 38 | 2023 |
| A One Pot Synthesis of Novel Bioactive Tri-Substitute-Condensed-Imidazopyridines that Targets Snake Venom Phospholipase A2 NC Anilkumar, MS Sundaram, CD Mohan, S Rangappa, KC Bulusu, ... PloS one 10 (7), e0131896, 2015 | 38 | 2015 |
| Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance V Serra, AT Wang, M Castroviejo-Bermejo, UM Polanska, M Palafox, ... Clinical Cancer Research 28 (20), 4536-4550, 2022 | 37 | 2022 |
| Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies D Módos, KC Bulusu, D Fazekas, J Kubisch, J Brooks, I Marczell, ... NPJ systems biology and applications 3 (1), 2, 2017 | 35 | 2017 |
| A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction MP Menden, D Wang, Y Guan, MJ Mason, B Szalai, KC Bulusu, T Yu, ... BioRxiv, 200451, 2017 | 29 | 2017 |
| Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework D Voulgarelis, KC Bulusu, JWT Yates Journal of Biological Dynamics 16 (1), 160-185, 2022 | 14 | 2022 |
| Graph neural networks including sparse interpretability C Lin, GJ Sun, KC Bulusu, JR Dry, M Hernandez arXiv preprint arXiv:2007.00119, 2020 | 14 | 2020 |